A283100 Stock Overview
Designs and develops genetic molecular diagnostics solutions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Novomics Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩410.00 |
52 Week High | ₩4,350.00 |
52 Week Low | ₩400.00 |
Beta | 0 |
11 Month Change | -33.55% |
3 Month Change | -49.75% |
1 Year Change | -89.86% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -94.64% |
Recent News & Updates
Recent updates
Shareholder Returns
A283100 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -19.6% | -12.6% | -12.2% |
1Y | -89.9% | 18.1% | -7.9% |
Return vs Industry: A283100 underperformed the KR Biotechs industry which returned 18.1% over the past year.
Return vs Market: A283100 underperformed the KR Market which returned -7.9% over the past year.
Price Volatility
A283100 volatility | |
---|---|
A283100 Average Weekly Movement | 14.4% |
Biotechs Industry Average Movement | 8.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in KR Market | 11.8% |
10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A283100's share price has been volatile over the past 3 months.
Volatility Over Time: A283100's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | n/a | www.novomics.com |
Novomics Co., Ltd. designs and develops genetic molecular diagnostics solutions. The company offers nProfiler1 Expansion Stomach Cancer Assay to analyze the gene expression profiles of stage II-III gastric cancer. It also provides nProfiler 2, a cancer variant assay; AI assisted digital pathology and auto sampling system; nProfiler, a breast cancer assay; nProfiler, a colon cancer assay; nProfiler, a rectal cancer assay; and nProfiler, a cOVID-19 detection kit.
Novomics Co., Ltd. Fundamentals Summary
A283100 fundamental statistics | |
---|---|
Market cap | ₩2.68b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A283100 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A283100 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A283100 perform over the long term?
See historical performance and comparison